Companies Response To Thrombosis Data Differs; New Definition Unveiled

Boston Scientific and Johnson & Johnson/Cordis had markedly different responses to analyses reported last week at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C. showing an increased risk of thrombosis from use of their drug-eluting stents (DES)